Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease
Alzheimer’s disease (AD) is a chronic, progressive and fatal neurodegenerative disease, and is considered to be the main cause of dementia. It is currently one of the most prevalent diseases in the world, counting with millions of people suffering from dementia. Its exact etiology is not yet known;...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Formifarma, LDA.
2022-03-01
|
| Series: | Revista Portuguesa de Farmacoterapia |
| Subjects: | |
| Online Access: | http://revista.farmacoterapia.pt/index.php/rpf/article/view/328 |
| _version_ | 1797733180882550784 |
|---|---|
| author | Maria Teresa Cruz Catarina Oliveira |
| author_facet | Maria Teresa Cruz Catarina Oliveira |
| author_sort | Maria Teresa Cruz |
| collection | DOAJ |
| description |
Alzheimer’s disease (AD) is a chronic, progressive and fatal neurodegenerative disease, and is considered to be the main cause of dementia. It is currently one of the most prevalent diseases in the world, counting with millions of people suffering from dementia. Its exact etiology is not yet known; however, among the various hypotheses trying to explain the pathophysiology of AD, the one that has been more prominent in clinical research is the amyloid cascade hypothesis. Therefore, researchers have been using immunotherapy, particularly passive immunization, based on the use of effective monoclonal antibodies against the amyloid-β aggregates. Currently, several antibodies are already in phase 3 clinical trials. On June 7th, 2021, the monoclonal antibody Aducanumab gains Food and Drug Administration (FDA) approval to be used in patients in the early stages of the disease, becoming the first disease modifying drug for AD, contrary to other drugs that are already on the market, which only act on symptomatology.
|
| first_indexed | 2024-03-12T12:25:27Z |
| format | Article |
| id | doaj.art-2218d57d0b6241cbba114ac2d50be8e8 |
| institution | Directory Open Access Journal |
| issn | 1647-354X 2183-7341 |
| language | English |
| last_indexed | 2024-03-12T12:25:27Z |
| publishDate | 2022-03-01 |
| publisher | Formifarma, LDA. |
| record_format | Article |
| series | Revista Portuguesa de Farmacoterapia |
| spelling | doaj.art-2218d57d0b6241cbba114ac2d50be8e82023-08-29T22:46:59ZengFormifarma, LDA.Revista Portuguesa de Farmacoterapia1647-354X2183-73412022-03-0113310.25756/rpf.v13i3.279Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s DiseaseMaria Teresa CruzCatarina Oliveira Alzheimer’s disease (AD) is a chronic, progressive and fatal neurodegenerative disease, and is considered to be the main cause of dementia. It is currently one of the most prevalent diseases in the world, counting with millions of people suffering from dementia. Its exact etiology is not yet known; however, among the various hypotheses trying to explain the pathophysiology of AD, the one that has been more prominent in clinical research is the amyloid cascade hypothesis. Therefore, researchers have been using immunotherapy, particularly passive immunization, based on the use of effective monoclonal antibodies against the amyloid-β aggregates. Currently, several antibodies are already in phase 3 clinical trials. On June 7th, 2021, the monoclonal antibody Aducanumab gains Food and Drug Administration (FDA) approval to be used in patients in the early stages of the disease, becoming the first disease modifying drug for AD, contrary to other drugs that are already on the market, which only act on symptomatology. http://revista.farmacoterapia.pt/index.php/rpf/article/view/328Alzheimer Disease/drug therapy; Alzheimer Disease/physiopathology; Amyloid beta-Peptides; Antibodies, Monoclonal; Clinical Trials |
| spellingShingle | Maria Teresa Cruz Catarina Oliveira Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease Revista Portuguesa de Farmacoterapia Alzheimer Disease/drug therapy; Alzheimer Disease/physiopathology; Amyloid beta-Peptides; Antibodies, Monoclonal; Clinical Trials |
| title | Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease |
| title_full | Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease |
| title_fullStr | Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease |
| title_full_unstemmed | Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease |
| title_short | Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease |
| title_sort | anti amyloid β monoclonal antibodies recent therapeutic strategies for alzheimer s disease |
| topic | Alzheimer Disease/drug therapy; Alzheimer Disease/physiopathology; Amyloid beta-Peptides; Antibodies, Monoclonal; Clinical Trials |
| url | http://revista.farmacoterapia.pt/index.php/rpf/article/view/328 |
| work_keys_str_mv | AT mariateresacruz antiamyloidbmonoclonalantibodiesrecenttherapeuticstrategiesforalzheimersdisease AT catarinaoliveira antiamyloidbmonoclonalantibodiesrecenttherapeuticstrategiesforalzheimersdisease |